AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
BeyondSpring Inc (NASDAQ:BYSI)
1.68 USD
0.000 0.000%| Previous Close (in USD) | 1.68 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 4.000/0.778 |
| EBITDA (in USD) | -16.715M |
| PE Ratio | -- |
| Volume | 4116 |
| Diluted Eps TTM | -0.40 |
| Total Assets (in USD) | 24.808M |
|---|---|
| Total Liabilities (in USD) | 48.269M |
| Revenue TTM (in USD) | 1.876M |
| Cash (in USD) | 17.75M |
| Market Cap (in USD) | 68.914 M |
| Revenue Per Share TTM | 0.048 |
| Gross Profit TTM (in USD) | 1.351M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
100 Campus Drive, Florham Park, NJ, United States, 07932
(646) 305-6387
Employees: 36
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Lan Huang | Co-Founder, Chairman & CEO | 1971 |
| 2. | Dr. G. Kenneth Lloyd | Chief Scientific Officer | 1944 |
| 3. | Dr. Ramon W. Mohanlal | Exec. VP of R&D, Chief Medical Officer and Director | 1958 |
| 4. | Mr. Linqing Jia | Co-Founder | NA |
| 5. | Stephen Kilmer | Head of Investor Relations | NA |
| 6. | Mr. Gregg Russo | Sr. VP of HR | NA |
| 7. | Dr. Lan Huang Ph.D. | Co-Founder, Chairman & CEO | 1971 |
| 8. | Dr. June Lu Ph.D. | Chief Scientific Officer | NA |
| 9. | Mr. Gregg Russo | Senior Vice President of Human Resources | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -36.117M | -64.638M | -63.821M | -40.333M | -57.474M |
| Minority Interest | 3.001M | 4.029M | 3.481M | 0.854M | -1.616M |
| Net Income | -36.28M | -68.208M | -61.062M | -38.291M | -54.869M |
| Selling General Administrative | 13.008M | 30.703M | 22.598M | 8.965M | 5.927M |
| Gross Profit | 1.351M | 1.351M | 0.18M | - | - |
| Reconciled Depreciation | 0.232M | 0.061M | 0.077M | 0.077M | 0.048M |
| Ebit | -37.239M | -66.24M | -64.211M | -40.307M | -57.09M |
| Ebitda | -35.439M | -64.721M | -64.014M | -40.046M | -57.042M |
| Depreciation And Amortization | 1.8M | 1.519M | 0.197M | 0.261M | 0.048M |
| Operating Income | -37.239M | -66.24M | -64.211M | -40.307M | -57.545M |
| Other Operating Expenses | 38.59M | 67.591M | 64.391M | 40.307M | 57.545M |
| Interest Expense | 0.017M | 0.087M | 0.085M | 0.206M | 0.071M |
| Tax Provision | 0.163M | 3.57M | 0M | 0M | 0M |
| Interest Income | 0.195M | 0.098M | 0.116M | 0.184M | 0.211M |
| Net Interest Income | 0.178M | 0.011M | 0.031M | -0.022M | 0.211M |
| Income Tax Expense | 0.163M | 3.57M | -2.759M | -2.042M | -2.676M |
| Total Revenue | 1.351M | 1.351M | 0.18M | 0M | 0M |
| Total Operating Expenses | 38.59M | 67.591M | 64.391M | 40.307M | 57.545M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 1.122M | 1.602M | 0.39M | -0.026M | -0.14M |
| Net Income From Continuing Ops | -36.28M | -68.208M | -63.821M | -40.333M | -57.474M |
| Net Income Applicable To Common Shares | - | -64.179M | -60.973M | -38.085M | -54.869M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 24.808M | 46.222M | 81.648M | 117.038M | 44.555M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.476M | 0.763M | 1.02M | 0.358M | 0.41M |
| Total Liab | 48.269M | 49.229M | 60.725M | 30.413M | 13.424M |
| Total Stockholder Equity | -26.805M | -5.979M | 26.684M | 88.34M | 30.277M |
| Other Current Liab | 4.169M | 3.954M | 10.023M | 9.413M | 0.065M |
| Common Stock | 0.004M | 0.004M | 0.004M | 0.004M | 0.003M |
| Capital Stock | 0.004M | 0.004M | 0.004M | 0.004M | 0.003M |
| Retained Earnings | -396.302M | -375.276M | -341.997M | -277.818M | -216.845M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | - | 3.119M | 1.28M | 0.946M |
| Cash | 17.75M | 34.396M | 41.625M | 109.537M | 35.933M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.958M | 7.352M | 15.155M | 13.766M | 10.053M |
| Current Deferred Revenue | 1.751M | 1.351M | 1.369M | 1.35M | 6.885M |
| Net Debt | -13.755M | -29.435M | -38.05M | -105.224M | -31.996M |
| Short Term Debt | 0.631M | 0.966M | 2.107M | 0.787M | 0.566M |
| Short Long Term Debt | - | - | 1.569M | - | 0.029M |
| Short Long Term Debt Total | 3.995M | 4.961M | 3.575M | 4.313M | 3.937M |
| Other Stockholder Equity | 368.599M | 368.857M | 369.2M | 366.451M | 246.979M |
| Property Plant Equipment | - | - | 3.406M | 2.358M | 2.747M |
| Total Current Assets | 18.419M | 38.523M | 75.123M | 113.4M | 40.862M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0.193M | 2.872M | 30.743M | - | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | 2.167M | 1.436M |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.407M | 1.081M | 1.656M | 2.216M | 2.537M |
| Accumulated Other Comprehensive Income | 0.894M | 0.436M | -0.523M | -0.297M | 0.14M |
| Non Currrent Assets Other | 0.364M | 0.347M | 1.575M | 1.28M | 0.946M |
| Non Current Assets Total | 6.389M | 7.699M | 6.525M | 3.638M | 3.693M |
| Capital Lease Obligations | 3.995M | 4.961M | 2.006M | 2.146M | 2.472M |
| Long Term Debt Total | - | - | - | - | 1.436M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 17.56M | -20.413M | -0.052M | -0.004M | 3.074M |
| Total Cashflows From Investing Activities | - | -20.413M | -0.052M | -0.004M | 2.867M |
| Total Cash From Financing Activities | 3.431M | 0.001M | 117.835M | 80.171M | 13.245M |
| Net Income | -36.28M | -68.208M | -63.821M | -40.333M | -57.474M |
| Change In Cash | -7.229M | -67.912M | 73.604M | 32.044M | -23.592M |
| Begin Period Cash Flow | 41.625M | 109.537M | 35.933M | 3.889M | 27.481M |
| End Period Cash Flow | 34.396M | 41.625M | 109.537M | 35.933M | 3.889M |
| Total Cash From Operating Activities | -27.464M | -47.242M | -43.745M | -48.162M | -39.955M |
| Depreciation | 0.232M | 0.061M | 0.077M | 0.077M | 0.048M |
| Other Cashflows From Investing Activities | - | - | - | - | 3.074M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 1.77M | 1.014M | -3.31M | 0.316M |
| Sale Purchase Of Stock | - | - | - | 69.454M | 14M |
| Other Cashflows From Financing Activities | 5M | 0.001M | 5.322M | 18.075M | -0.755M |
| Capital Expenditures | 0.034M | 2.844M | 0.052M | 0.004M | 0.207M |
| Change In Working Capital | 6.409M | 18.408M | 11.146M | -10.007M | 11.218M |
| Other Non Cash Items | 0.509M | 0.546M | 0.659M | -2.248M | -0.307M |
| Free Cash Flow | -27.498M | -50.086M | -43.797M | -48.166M | -40.162M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Guggenheim Active Allocation Fund | 1 year ago | 133 |
| 2. | ST Healthcare Innovations 12 CA | 1 year ago | 100 |
| 3. | iShares Micro-Cap ETF | 6 months ago | 52810 |
| 4. | Fidelity Nasdaq Composite Index | 7 months ago | 24368 |
| 5. | Northern Small Cap Core I | 8 months ago | 5459 |
| 6. | AVIP BlackRock Advtg Small Cp Gr Prtfl | 8 months ago | 5417 |
| 7. | JHVIT Total Stock Market Index I | 8 months ago | 4986 |
| 8. | 1290 VT Micro Cap K | 8 months ago | 4632 |
| 9. | NT Quality SCC US Fund - L | 11 months ago | 3539 |
| 10. | BlackRock Advtg Asia ex Jpn Eq D GBP Acc | 9 months ago | 3361 |
| 11. | NT Quality Small Cap Core | 8 months ago | 3353 |
| 12. | Guggenheim Active Allocation Fund | 9 months ago | 133 |
| 13. | ST Healthcare Innovations 12 CA | 1 year ago | 100 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Citigroup Inc | 8 months ago | 250000 |
| 2. | FMR Inc | 11 months ago | 0 |
| 3. | SG Americas Securities, LLC | 11 months ago | 0 |
| 4. | Decheng Capital LLC | 8 months ago | 4958143 |
| 5. | BlackRock Inc | 11 months ago | 215355 |
| 6. | Tanaka Capital Management Inc | 8 months ago | 29473 |
| 7. | Geode Capital Management, LLC | 8 months ago | 24368 |
| 8. | Northern Trust Corp | 8 months ago | 16705 |
| 9. | Renaissance Technologies Corp | 8 months ago | 11700 |
| 10. | XTX Topco Ltd | 8 months ago | 10332 |
| 11. | Bank of America Corp | 8 months ago | 8000 |
| 12. | Morgan Stanley - Brokerage Accounts | 8 months ago | 7910 |
| 13. | UBS Group AG | 8 months ago | 6381 |
| 14. | Citadel Advisors Llc | 8 months ago | 5232 |
| 15. | Wells Fargo & Co | 8 months ago | 580 |
| 16. | Barclays PLC | 8 months ago | 4 |
| 17. | State Street Corp | 11 months ago | 0 |
| 18. | Acadian Asset Management LLC | 11 months ago | 0 |
| 19. | Royal Bank of Canada | 8 months ago | 0 |
| 20. | Capstone Capital Wealth Advisors | 11 months ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...